Patients with Advanced Cancer Survive 10 Years on Targeted Cancer Drug Imatinib

The article reports long-term results from a major international clinical trial in which fifth of patients with advanced gastrointestinal stromal tumours (GIST) continue to survive a decade after first taking the targeted drug imatinib, also known as Glivec, one of the first targeted drug that was approved by the FDA. Some 10% of patients are still on the trial after 10 years, living free of any progression of their cancer.

read more

Making precision oncology the standard of care

The article discusses a large scale clinical study using a comprehensive assay that was conducted in Memorial Sloan Kettering Cancer Center and highlight the need to characterize currently unknown driver mutations.

read more

Implementing Genome-Driven Oncology

In this review article physicians from Memorial Sloan-Kettering Cancer Center describe the related challenges associated with implementing ‘Genome-Driven’ oncology.

read more